Article Details

AstraZeneca nabs FDA nod to challenge GSK's Benlysta with first-in-class lupus drug Saphnelo

Retrieved on: 2021-08-02 13:07:30

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca nabs FDA nod to challenge GSK's Benlysta with first-in-class lupus drug Saphnelo. View article details on hiswai:

Excerpt

After a ten-year drought in new treatments for systemic lupus, the FDA has waved through a new drug. The FDA cleared AstraZeneca's Saphnelo ( ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up